Global Anal Fistula Treatment Market By By Treatment Type (Non-surgical (H2 Blockers, Antidiarrheals, Fibrin Glue, Adipose Stem Cell Therapy, and Others) and Surgical (Fistulotomy, Advancement Flap Procedures, Bioprosthetic Plugs, Seton techniques, and Others)), By Application (Intersphincteric Fistula, Suprasphincteric Fistula, Transsphincteric Fistula, and Others), By End-user (Hospitals, Ambulatory Surgical Centers, and Others), Region and Companies – Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2024-2033

Report Overview

The Global Anal Fistula Treatment Market size is expected to be worth around USD 1,148.6 million by 2033 from USD 761.2 million in 2023, growing at a CAGR of 4.2% during the forecast period 2024 to 2033.

The market is likely to grow due to several factors, including the increasing prevalence of anal fistulas, advancements in treatment technologies, and growing healthcare expenditure.  The market offers substantial lucrative prospects for growth, particularly in emerging economies where access to healthcare is expanding. Rising awareness about anal fistula treatments and growing demand for minimally invasive procedures are also fueling the market. The market is also expected to benefit from the increasing adoption of biologics and emerging technologies.

Increased prevalence of inflammatory bowel diseases including Crohn’s disease and ulcerative colitis, the introduction of innovative products, and rising consumer desire for non-surgical methods like fibrin glue injection and adipose-derived stem cell treatment are the main factors driving the market’s expansion.

A 2022 study carried out by researchers at the University of Nottingham with funding from Crohn’s & Colitis UK and Coeliac UK revealed that the prevalence of Crohn’s and Colitis in the UK is significantly higher. It also showed that 1 in 123 people in the UK has either ulcerative colitis or Crohn’s disease, meaning that there are approximately 500,000 people with inflammatory bowel disease (IBD) in the UK.

Key Takeaways

• Market Size: The Global Anal Fistula Treatment Market size is expected to be worth around USD 1,148.6 million by 2033 from USD 761.2 million in 2023.
• Market Growth: The market growing at a CAGR of 4.2% during the forecast period 2024 to 2033.
• Type Analysis: The treatment type segment is divided into non-surgical and surgical, with surgical taking the lead in 2023 with a market share of 62.7%.
• Application Analysis: Considering application, the market is divided into intersphincteric fistula, suprasphincteric fistula, transsphincteric fistula, and others. Among these, intersphincteric fistula held a significant share of 56.1%.
• End-Use Analysis: The market is segregated into hospitals. The hospitals sector stands out as the dominant player, holding the largest revenue share of 73.2% in the Anal Fistula Treatment market.
• Regional Analysis: North America led the market by securing a market share of 43.2% in 2023.

Treatment Type Analysis

The surgical segment led in 2023, claiming a market share of 62.7% owing to the rising incidence of anal fistulas and the availability of surgical procedures as a treatment option. Technological improvements in surgical processes such as FiLaC and VAAFT are contributing to the market’s growth in this segment.

These procedures are being practiced widely because of high success rates, fewer post-operative complications, and early recovery. Moreover, the surge in the number of patients opting for surgical procedures as the surgery provides permanent treatment is driving the market.

Application Analysis

The intersphincteric fistula held a significant share of 56.1% due to the higher incidence rate of the disease among patients. This segment is likely to remain the most significant in the market because of the rising use of minimally invasive procedures such as FiLaC and VAAFT which are efficient treatments of intersphincteric fistula.

Furthermore, the growing prevalence of inflammatory bowel diseases such as Crohn’s disease and ulcerative colitis is anticipated to drive the demand for intersphinteric fistula treatment. This, along with the technological advancements in anal fistula treatment are expected to create lucrative prospects for the growth of this segment during the assessment period.

End-user Analysis

The hospitals segment had a tremendous growth rate, with a revenue share of 73.2% as an increasing number of patients are being diagnosed with anal fistula and undergoing treatment in hospitals. This segment is also growing due to the increasing healthcare costs and increasing need for better quality of care.

Hospitals are using enhanced procedures and tools in carrying out surgeries including laser treatment to minimize adverse effects. The presence of specialized colorectal surgeons and gastroenterologists in hospitals is also creating lucrative prospects for the growth of this segment.

Key Market Segments

By Treatment Type

• Non-surgical
  • H2 Blockers
  • Antidiarrheals
  • Fibrin Glue
  • Adipose Stem Cell Therapy
  • Others
• Surgical
  • Fistulotomy
  • Advancement Flap Procedures
  • Bioprosthetic Plugs
  • Seton techniques
  • Others

By Application

• Intersphincteric Fistula
• Suprasphincteric Fistula
• Transsphincteric Fistula
• Others

By End-user

• Hospitals
• Ambulatory Surgical Centers
• Others

Drivers

Increasing Prevalence of Inflammatory Diseases

The growing prevalence of inflammatory diseases such as Crohn’s disease and ulcerative colitis is the key factor for the anal fistula treatment market as these patients are at a higher risk of contracting anal fistulas. Fistulas are formed due to chronic inflammation as a result of inflammatory diseases which affect the anal gland. Since the prevalence of these diseases is on the rise, the population of patients suffering from anal fistulas also grows, creating a need for efficient therapies. This, along with the new developments in the treatment of anal fistulas, drives the market.

• As per the data updated by the Centers for Disease Control & Prevention in June 2024, the occurrence of inflammatory bowel disease (IBD) in the US is assessed to be in the range of 2.4 – 3.1 million. It is estimated that both, IBD prevalence as well as healthcare costs are rising.

Restraints

High Cost of Treatment

The expensive nature of the treatment is a key factor that hinders the market since it makes it difficult for low- to mid-income household patients to seek the treatment they need. Even in developed countries, high copays and coinsurance rates can deter patients from seeking treatment. The financial burden of treatment can lead to delayed or foregone care, reducing demand for anal fistula treatment.

As a result, the high cost of treatment hinders market growth, particularly in price-sensitive markets, and creates a need for more affordable treatment options.

Opportunities

Growing adoption of Modern Lifestyle and Unhealthy Eating Habits

The growing adoption of modern lifestyles and unhealthy eating habits opens up lucrative prospects for the market. Habits such as excessive consumption of processed food, heavy smoking and drinking, irregular sleep cycles, and eating an unbalanced diet devoid of fibers lead to inflammation in the body, which over a certain period, leads to problems such as obesity and chronic constipation.

This causes strain during bowel movements and an increased pressure on the anal glands, leading to fistula formation. Modern lifestyle factors such as sedentary behavior and stress also contribute to fistula formation. As the prevalence of these lifestyle factors increases, so does the demand for anal fistula treatments, creating profitable projections for the market.

According to the data updated by the Economic Times in August 2023, there has been a significant rise in the number of patients suffering from inflammatory bowel disease in India. A study from the Asian Institute of Gastroenterology (AIG), IBD Center, of Hyderabad, India, shows that the occurrence of inflammatory bowel disease (IBD) has risen from 0.1% to more than 5% in the last 16 years in the region.

Impact of Macroeconomic / Geopolitical Factors

Macroeconomic and geopolitical factors exert a significant influence on the Anal Fistula Treatment market, shaping its growth trajectory and dynamics. The anal fistula treatment is impacted by macroeconomic factors such as healthcare expenditure, insurance coverage, and economic growth, which can influence demand and access to treatment. Geopolitical factors like tariffs, trade policies, and global conflicts can impact the availability and cost of treatment options.

However, growing healthcare investment in emerging economies is a positive trend driving the market. Additionally, the advancements in medical technology and rising awareness about anal fistula treatment are expected to expand the market.

Latest Trends

Increasing Adoption of Minimally Invasive Procedures

Minimally invasive procedures such as Fistula-tract Laser Closure (FiLaC) and Video-assisted Anal Fistula Treatment (VAAFT) are rapidly gaining popularity among patients. These procedures offer reduced post-operative pain, faster recovery, and fewer complications in comparison to traditional surgical methods.

Advances in technology and instrumentation have improved the efficacy and safety of these procedures. As a result, minimally invasive procedures are becoming the preferred choice for anal fistula treatment, driving market growth and innovation.

According to the Central Asian Journal of Medical and Natural Science, it was found that laser fistula surgery has a high rate of success with lower pain levels, minimal complications, and improved life quality. This suggests that laser surgery is an ideal treatment for fistulas, enabling fast recovery and small recurrence rates.

Regional Analysis

North America is leading the Anal Fistula Treatment Market

North America dominated the market with the highest revenue share of 43.2% owing to the growing prevalence of anal fistulas and rising demand for advanced treatments. The growing adoption of minimally invasive procedures and biologics will contribute to market growth, with the US dominating the market due to its large patient population and high adoption of advanced treatments. The market is likely to grow in the near future as a result of increasing awareness and improving healthcare infrastructure.

Additionally, the presence of several key market players and ongoing research & development activities are projected to further boost the market in this region. As per the 2022 report of the Mayo Clinic, a US-based nonprofit system of hospitals with campuses in Scottsdale and Phoenix, Arizona; Rochester, Minnesota; and Jacksonville, Florida, more than 1,000 patients suffering from anal fistulas are treated by the surgeons of this clinic every year.

The Europe region is expected to experience the highest CAGR during the forecast period

Europe is expected to grow with the fastest CAGR owing to factors such as aging population, increasing occurrence of anal fistulas, and a surge in demand for advanced treatments. The high adoption of minimally invasive procedures, such as laser surgery, and the high use of biologics is anticipated to contribute to the market’s growth. The market is further driven by high healthcare expenditure, well-established healthcare infrastructure, and growing awareness for anal fistula treatment.

According to the recent data from the Sage Journals, approximately 2.5–3 million people (0.4%) in Europe are suffering from inflammatory bowel disease (IBD). Although the incidence rates for IBD are stabilizing throughout Europe, the prevalence is surging, resulting in a substantial cost to the healthcare system, which is estimated to be 4.6–5.6 billion euros every year.

Key Regions and Countries

North America

• US
• Canada

Europe

• Germany
• France
• The UK
• Spain
• Italy
• Russia
• Netherland
• Rest of Europe

Asia Pacific

• China
• Japan
• South Korea
• India
• New Zealand
• Singapore
• Thailand
• Vietnam
• Rest of APAC

Latin America

• Brazil
• Mexico
• Rest of Latin America

Middle East & Africa

• South Africa
• Saudi Arabia
• UAE
• Rest of MEA

Key Players Analysis

Innovative medicines and treatment plans are being actively developed by major players in the anal fistula treatment market. Additionally, they are implementing strategic initiatives to improve their economic position. The objective of these endeavors is to enhance the efficacy of treatment and the quality of patient outcomes, all while broadening the market.

These companies endeavor to address unmet medical needs and enhance their competitive position in the anal fistula treatment market by utilizing research and development, partnerships, and acquisitions.

Top Key Players

• Valeant Pharmaceuticals International Inc.
• Teva Pharmaceutical Industries Ltd.
• Taro Pharmaceutical Inc.
• Takeda
• Pfizer Inc.
• Ossium Health, Inc.
• GlaxoSmithKline Plc.
• Eisai Co Ltd.
• Cigna
• Bayer AG
• AstraZeneca
• Allergan Inc.
• Abbott Laboratories

Recent Developments

• In March 2022, the United States Food and Drug Administration (FDA) accepted Ossium Health, Inc.’s Investigational New Drug (IND) application for OSSM-001, a mesenchymal stem cell (MSC) product intended to treat refractory perianal fistulas in Crohn’s disease patients.
• In February 2022, Takeda announced the first six-month interim analysis findings from INSPIRE. Of the patients in both cohorts examined at six months, 65% showed evidence of clinical remission. The European post-approval, observational, multicenter INSPIRE research (EUPAS24267) assesses the safety and practical efficacy of Alofisel (darvadstrocel) in patients with complicated perianal fistulas and Crohn’s disease (CD).

Report Scope